ReviewWorld journal of hepatology2022
Emerging curative-intent minimally-invasive therapies for hepatocellular carcinoma.
Review in World journal of hepatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 31 citations in OpenAlex.
- Review
- Comparative analysis of radiation therapy and surgical approaches for resectable cancers: a narrative review.Annals of medicine and surgery (2012) · 2026Review
- Hepatocellular Carcinoma Bridging and Downstaging: Advances in Locoregional Therapy.Biomedicines · 2026Review
- The State of the Art in Combination Locoregional and Systemic Treatment Strategies for Hepatocellular Carcinoma: Recent Advancements and Future Horizons.Current oncology (Toronto, Ont.) · 2026Review
- Advances and Emerging Techniques in Transarterial Chemoembolization for Hepatocellular Carcinoma.Cancers · 2026Review
- Tumor calcification and sustained complete response after chemoembolization in hepatocellular carcinoma: Two case reports and review of literature.World journal of gastrointestinal oncology · 2025Article
- Review
- Modern approach to hepatocellular carcinoma treatment.World journal of hepatology · 2025Review
- Biliary and respiratory complications after right hepatectomy for hepatocellular carcinoma following selective internal radiation therapy (SIRT): a retrospective case-control study.Hepatobiliary surgery and nutrition · 2025Article
- Review
- Advances and Emerging Techniques in Y-90 Radioembolization for Hepatocellular Carcinoma.Cancers · 2025Review
- Precision oncology: The role of minimally-invasive ablation therapy in the management of solid organ tumors.World journal of radiology · 2025Review
- HN1-mediated activation of lipogenesis through Akt-SREBP signaling promotes hepatocellular carcinoma cell proliferation and metastasis.Cancer gene therapy · 2024Article
- Yttrium-90 radioembolization treatment strategies for management of hepatocellular carcinoma.World journal of radiology · 2024Review
- Locoregional Therapies for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.Biomedicines · 2024Review
- Article
- Review
- Hepatocellular carcinoma outcomes and potential implications for surveillance in elderly patients.Scientific reports · 2024Article
- Review
- Examining the Efficacy and Safety of Combined Locoregional Therapy and Immunotherapy in Treating Hepatocellular Carcinoma.Biomedicines · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the most common cause of liver malignancy and the fourth leading cause of cancer deaths universally. Cure can be achieved for early stage HCC, which is defined as 3 or fewer lesions less than or equal to 3 cm in the setting of Child-Pugh A or B and an ECOG of 0. Patients outside of these criteria who can be down-staged with loco-regional therapies to resection or liver transplantation (LT) also achieve curative outcomes. Traditionally, surgical resection, LT, and ablation are considered curative therapies for early HCC. However, results from recently conducted LEGACY study and DOSISPHERE trial demonstrate that transarterial radio-embolization has curative outcomes for early HCC, leading to its recent incorporation into the Barcelona clinic liver criteria guidelines for early HCC. This review is based on current evidence for curative-intent loco-regional therapies including radioembolization for early-stage HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.